Company / Cash & Equivalents
Praxis Precision Medicines, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$357.3M
FY2025
5-year range
$61.6M / $357.3M
FY2021-FY2025
Trend
+65.9%
vs FY2024
Sector context
#54 of 207
Health Care
What the data says
At $357M, Praxis Precision Medicines, Inc.'s cash & equivalents ranks #54 of 207 in the Health Care sector. Cash & Equivalents has increased for 3 consecutive years, from $62M in FY2022 to $357M in FY2025.
Based on SEC 10-K filings.
$357M in FY2025 with a 5-year CAGR of +3.8%.
Improved from $81M to $357M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +79.7%
- 5-Year CAGR
- +3.8%
- 10-Year CAGR
- -
Sector benchmark
#54 of 207 in Health CareTop 26% of 207This company $357.3M Sector average $669.5M
▼
-46.6% below sector average
Key checks
Key Insights
- Praxis Precision Medicines, Inc.'s cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of +3.8%, indicating consistent growth.
- In FY2025, cash & equivalents increased 65.9% year-over-year.
- Ranks #54 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 4.48 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $357.3M | +65.9% |
| FY2024 | $215.4M | +164.9% |
| FY2023 | $81.3M | +31.9% |
| FY2022 | $61.6M | -55.6% |
| FY2021 | $138.7M | -53.2% |
| FY2020 | $296.6M | +561.8% |
| FY2019 | $44.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026